The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
Open accessAbstract
Monoclonal antibodies are among the most promising therapeutic agents for treating cancer. Therapeutic cancer antibodies bind to tumor cells, turning them into targets for immune-mediated destruction. We show here that this antibody-mediated killing of tumor cells is limited by a mechanism involving the interaction between tumor cell-expressed CD47 and the inhibitory receptor signal regulatory protein-α (SIRPα) on myeloid cells. Mice that lack the SIRPα cytoplasmic tail, and hence its inhibitory signaling, display increased antibody-mediated elimination of melanoma cells in vivo. Moreover, interference with CD47–SIRPα interactions by CD47 knockdown or by antagonistic antibodies against CD47 or SIRPα significantly enhances the in vitro killing of trastuzumab-opsonized Her2/Neu-positive breast cancer cells by phagocytes. Finally, the response to trastuzumab therapy in breast cancer patients appears correlated to cancer cell CD47 expression. These findings demonstrate that CD47–SIRPα interactions participate in a homeostatic mechanism that restricts antibody-mediated killing of tumor cells. This provides a rational basis for targeting CD47–SIRPα interactions, using for instance the antagonistic antibodies against human SIRPα described herein, to potentiate the clinical effects of cancer therapeutic antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,970
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“ADCC can be mediated by Fc receptor-expressing natural killer (NK) cells and phagocytes, including macrophages and granulocytes (7, 8), and a link between FcγRIIa (CD32a) and FcγRIIIa (CD16) polymorphisms and clinical trastuzumab responsiveness in patients with breast cancer suggests an involvement of both types of Fc…”
BackgroundA family of proteins that inhibit signalling through tyrosine kinase receptors
Kharitonenkov, A., Chen, Z., Sures, I., Wang, H., Schilling, J., & Ullrich, A. (1997) · Nature · doi:10.1038/386181a0 · Cited by 662
Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells
Takenaka, K., Prasolava, T. K., Wang, J. C. Y., Mortin-Toth, S. M., Khalouei, S., Gan, O. I., Dick, J. E., & Danska, J. S. (2007) · Nature Immunology · doi:10.1038/ni1527 · Cited by 509
Cd47-Signal Regulatory Protein α (Sirpα) Regulates Fcγ and Complement Receptor–Mediated Phagocytosis
Oldenborg, P.-A., Gresham, H. D., & Lindberg, F. P. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.855 · Cited by 452
Fujioka, Y., Matozaki, T., Noguchi, T., Iwamatsu, A., Yamao, T., Takahashi, N., Tsuda, M., Takada, T., & Kasuga, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6887 · Cited by 448
Self-citationThe SIRP family of receptors and immune regulation
Barclay, A. N., & Brown, M. H. (2006) · Nature Reviews Immunology · doi:10.1038/nri1859 · Cited by 426
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., & Majeti, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2238 · Cited by 382
Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule
Jiang, P., Lagenaur, C. F., & Narayanan, V. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.559 · Cited by 351
Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers
Bertucci, F., Finetti, P., Cervera, N., Charafe-Jauffret, E., Mamessier, E., Adélaïde, J., Debono, S., Houvenaeghel, G., Maraninchi, D., Viens, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0031 · Cited by 310
Self-citationNegative Regulation of Phagocytosis in Macrophages by the CD47-SHPS-1 System
Okazawa, H., Motegi, S.-I., Ohyama, N., Ohnishi, H., Tomizawa, T., Kaneko, Y., Oldenborg, P.-A., Ishikawa, O., & Matozaki, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2004 · Cited by 302
Self-citationA gene expression signature identifies two prognostic subgroups of basal breast cancer
Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., Tallet, A., Chabannon, C., Extra, J.-M., Jacquemier, J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0897-9 · Cited by 290
Self-citationSignal-Regulatory Protein Is Selectively Expressed by Myeloid and Neuronal Cells
Adams, S., van der Laan, L. J. W., Vernon-Wilson, E., Renardel de Lavalette, C., Döpp, E. A., Dijkstra, C. D., Simmons, D. L., & van den Berg, T. K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1853 · Cited by 258
Self-citationHarris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
Latour, S., Tanaka, H., Demeure, C., Mateo, V., Rubio, M., Brown, E. J., Maliszewski, C., Lindberg, F. P., Oldenborg, A., Ullrich, A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2547 · Cited by 238
Barok, M., Isola, J., Pályi-Krekk, Z., Nagy, P., Juhász, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0766 · Cited by 231
Olsson, M., Bruhns, P., Frazier, W. A., Ravetch, J. V., & Oldenborg, P.-A. (2005) · Blood · doi:10.1182/blood-2004-08-2980 · Cited by 216
Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
Oldham, R. K., & Dillman, R. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7438 · Cited by 204
Signal Regulatory Proteins in the Immune System
van Beek, E. M., Cochrane, F., Barclay, A. N., & van den Berg, T. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7781 · Cited by 204
Self-citationTimms, J. F., Carlberg, K., Gu, H., Chen, H., Kamatkar, S., Nadler, M. J. S., Rohrschneider, L. R., & Neel, B. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3838 · Cited by 199
Hara, I., Takechi, Y., & Houghton, A. N. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1609 · Cited by 184
Seiffert, M., Brossart, P., Cant, C., Cella, M., Colonna, M., Brugger, W., Kanz, L., Ullrich, A., & Bühring, H.-J. (2001) · Blood · doi:10.1182/blood.v97.9.2741 · Cited by 183
Kretz-Rommel, A., Qin, F., Dakappagari, N., Ravey, E. P., McWhirter, J., Oltean, D., Frederickson, S., Maruyama, T., Wild, M. A., Nolan, M.-J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5595 · Cited by 178
CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα 1
Vernon-Wilson, E. F., Kee, W.-J., Willis, A. C., Barclay, A. N., Simmons, D. L., & Brown, M. H. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000)30:18<2130::aid-immu2130>3.0.co;2-p · Cited by 176
Renaissance of cancer therapeutic antibodies
Glennie, M. J., & van de Winkel, J. G. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02714-4 · Cited by 155
McWhirter, J. R., Kretz-Rommel, A., Saven, A., Maruyama, T., Potter, K. N., Mockridge, C. I., Ravey, E. P., Qin, F., & Bowdish, K. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510081103 · Cited by 154
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 147
Yamao, T., Noguchi, T., Takeuchi, O., Nishiyama, U., Morita, H., Hagiwara, T., Akahori, H., Kato, T., Inagaki, K., Okazawa, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203287200 · Cited by 140
Self-citationIshikawa-Sekigami, T., Kaneko, Y., Okazawa, H., Tomizawa, T., Okajo, J., Saito, Y., Okuzawa, C., Sugawara-Yokoo, M., Nishiyama, U., Ohnishi, H., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1896 · Cited by 119
Self-citationSpiridon, C., Guinn, S. E., & Vitetta, E. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0549 · Cited by 91
Kretz-Rommel, A., Qin, F., Dakappagari, N. K., Cofiell, R., Faas, S. J., & Bowdish, K. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.699 · Cited by 90
van den Berg, T. K., & van der Schoot, C. E. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.004 · Cited by 81
Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma
van Spriel, A. B., van Ojik, H. H., Bakker, A., Jansen, M., & van de Winkel, J. G. J. (2002) · Blood · doi:10.1182/blood.v101.1.253 · Cited by 79
Structure of Signal-regulatory Protein α
Hatherley, D., Graham, S. C., Harlos, K., Stuart, D. I., & Barclay, A. N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017566 · Cited by 44
Cited by
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Kraehenbuehl, L., Weng, C.-H., Eghbali, S., Wolchok, J. D., & Merghoub, T. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00552-7 · Cited by 846
Barclay, A. N., & van den Berg, T. K. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120142 · Cited by 841
Metadata
- Authors
- Zhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., Birnbaum, D., van Elsas, A., Kuijpers, T. W., Bertucci, F., & van den Berg, T. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-10-31
- Volume
- 108
- Issue
- 45
- Pages
- 18342-18347
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2091133773
- Cited by
- 276
- References
- 37
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.